Page 2 - Johan Dalsgaard News Today

/PRNewswire/ -- Vicore Pharma Holding AB (publ) ("Vicore" or the "Company"), a pioneer in the development of angiotensin II type 2 receptor agonists (ATRAGs),...

The new results show stabilization of disease already from week 6 and confirm the unprecedented increase in lung function over timeVicore will accelerate clinical developmentInvitation to conference

/PRNewswire/ -- Vicore Pharma Holding AB (publ) (Vicore) pioneering development of angiotensin II type 2 receptor agonists (ATRAGs), today announces positive...

GOTHENBURG, Sweden, Sept. 22, 2022 /PRNewswire/ -- Vicore Pharma Holding AB (publ) ("Vicore"), a...

GOTHENBURG, Sweden, Aug. 19, 2022 /PRNewswire/ -- Vicore Pharma Holding AB (publ) ("Vicore"), a clinical-stage pharmaceutical company developing medicines targeting the angiotensin II type 2

The AIR trial is a single arm, multicenter phase 2 study in patients with idiopathic pulmonary fibrosis (IPF)Interim data have shown stabilization of the disease and an increase in lung capacity

First healthy volunteer dosed with C106 in a phase 1 trialC106 is the first new angiotensin II type 2 receptor agonist (ATRAG) from Vicore's VP03 programTopline data expected Q1 2023GOTHENBURG

/PRNewswire/ -- Vicore Pharma Holding AB (publ) ("Vicore"), a clinical-stage pharmaceutical company developing medicines targeting the angiotensin II type 2...

First clinical study with a digital therapy (DTx) in patients with IPF to address the psychological symptom burden in this diseaseFirst patient enrolled in US pilot phase leading up to the US

/PRNewswire/ -- Vicore Pharma Holding AB (publ) ("Vicore"), a clinical-stage pharmaceutical company, today announces the first patient enrolled in the pilot...